106 related articles for article (PubMed ID: 3796760)
1. Predicting response to tamoxifen in metastatic breast cancer.
Connor JL; Foley JF; Lemon HM
Nebr Med J; 1986 Dec; 71(12):422-6. PubMed ID: 3796760
[No Abstract] [Full Text] [Related]
2. [The estrogen receptor in breast carcinoma in male patients and the tamoxifen response].
Gómez Cruz P; Rivadeneyra Hinojosa J; García-Alonso H; Rábago Velasco M
Ginecol Obstet Mex; 1988 Nov; 56():310-4. PubMed ID: 2856451
[No Abstract] [Full Text] [Related]
3. HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study.
Elledge RM; Green S; Ciocca D; Pugh R; Allred DC; Clark GM; Hill J; Ravdin P; O'Sullivan J; Martino S; Osborne CK
Clin Cancer Res; 1998 Jan; 4(1):7-12. PubMed ID: 9516946
[TBL] [Abstract][Full Text] [Related]
4. Use of tamoxifen in advanced male breast cancer.
Patterson JS; Battersby LA; Bach BK
Cancer Treat Rep; 1980; 64(6-7):801-4. PubMed ID: 7427964
[TBL] [Abstract][Full Text] [Related]
5. [The importance of steroid receptors for the prognosis and hormone treatment of breast cancer patients: a retrospective study in Southeastern Netherlands].
Voogd AC; Crommelin MA; Repelaer van Driel OJ; Tutein Nolthenius-Puylaert MC; Vreugdenhil G; Coebergh JW
Ned Tijdschr Geneeskd; 1998 Aug; 142(31):1772-8. PubMed ID: 9856143
[TBL] [Abstract][Full Text] [Related]
6. The nature of tamoxifen action in the control of female breast cancer.
Kodama M; Kodama T
In Vivo; 2001; 15(4):319-25. PubMed ID: 11695224
[TBL] [Abstract][Full Text] [Related]
7. Tamoxifen versus tamoxifen + mitoxantrone treatment in metastatic breast cancer.
Kars A; Baltali E; Tekuzman G; Firat D; Alakavuklar M
J Chemother; 1989 Jul; 1(4 Suppl):1196-7. PubMed ID: 16312831
[No Abstract] [Full Text] [Related]
8. Aminoglutethimide as second line endocrine therapy in advanced breast cancer.
Brufman G; Biran S
Anticancer Res; 1986; 6(5):1065-8. PubMed ID: 3800315
[TBL] [Abstract][Full Text] [Related]
9. [Tamoxifen (Nolvadex): therapeutic effect in metastasizing breast cancer].
Mouridsen HT; Palshof T; Patterson J; Battersby L
Ugeskr Laeger; 1979 Jul; 141(31):2108-13. PubMed ID: 483408
[No Abstract] [Full Text] [Related]
10. Prognostic factors affecting response to aminoglutethimide in advanced breast cancer.
Brufman G
Anticancer Res; 1993; 13(4):1235-7. PubMed ID: 8352549
[TBL] [Abstract][Full Text] [Related]
11. Clinical experiences with tamoxifen for estrogen receptor blocking therapy in metastatic breast cancer.
Henningsen B
Prog Clin Biol Res; 1977; 12():479-82. PubMed ID: 918118
[No Abstract] [Full Text] [Related]
12. Randomized trial of tamoxifen alone or combined with fluoxymesterone as adjuvant therapy in postmenopausal women with resected estrogen receptor positive breast cancer. North Central Cancer Treatment Group Trial 89-30-52.
Ingle JN; Suman VJ; Mailliard JA; Kugler JW; Krook JE; Michalak JC; Pisansky TM; Wold LE; Donohue JH; Goetz MP; Perez EA
Breast Cancer Res Treat; 2006 Jul; 98(2):217-22. PubMed ID: 16538529
[TBL] [Abstract][Full Text] [Related]
13. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.
Fisher B; Costantino JP; Wickerham DL; Cecchini RS; Cronin WM; Robidoux A; Bevers TB; Kavanah MT; Atkins JN; Margolese RG; Runowicz CD; James JM; Ford LG; Wolmark N
J Natl Cancer Inst; 2005 Nov; 97(22):1652-62. PubMed ID: 16288118
[TBL] [Abstract][Full Text] [Related]
14. Heat shock proteins hsp27 and hsp70: lack of correlation with response to tamoxifen and clinical course of disease in estrogen receptor-positive metastatic breast cancer (a Southwest Oncology Group Study).
Ciocca DR; Green S; Elledge RM; Clark GM; Pugh R; Ravdin P; Lew D; Martino S; Osborne CK
Clin Cancer Res; 1998 May; 4(5):1263-6. PubMed ID: 9607585
[TBL] [Abstract][Full Text] [Related]
15. Tamoxifen for patients with estrogen receptor-negative breast cancer.
Swain SM
J Clin Oncol; 2001 Sep; 19(18 Suppl):93S-97S. PubMed ID: 11560981
[No Abstract] [Full Text] [Related]
16. Tamoxifen therapy in premenopausal patients with metastatic breast cancer.
Pritchard KI; Thomson DB; Myers RE; Sutherland DJ; Mobbs BG; Meakin JW
Cancer Treat Rep; 1980; 64(6-7):787-96. PubMed ID: 7427962
[TBL] [Abstract][Full Text] [Related]
17. Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer.
Foekens JA; Diamandis EP; Yu H; Look MP; Meijer-van Gelder ME; van Putten WL; Klijn JG
Br J Cancer; 1999 Feb; 79(5-6):888-94. PubMed ID: 10070886
[TBL] [Abstract][Full Text] [Related]
18. How ADAM-9 and ADAM-11 differentially from estrogen receptor predict response to tamoxifen treatment in patients with recurrent breast cancer: a retrospective study.
Sieuwerts AM; Meijer-van Gelder ME; Timmermans M; Trapman AM; Garcia RR; Arnold M; Goedheer AJ; Portengen H; Klijn JG; Foekens JA
Clin Cancer Res; 2005 Oct; 11(20):7311-21. PubMed ID: 16243802
[TBL] [Abstract][Full Text] [Related]
19. Tamoxifen therapy in premenopausal women with metastatic breast cancer.
Planting AS; Alexieva-Figusch J; Blonk-vdWijst J; van Putten WL
Cancer Treat Rep; 1985 Apr; 69(4):363-8. PubMed ID: 3995508
[TBL] [Abstract][Full Text] [Related]
20. Tamoxifen induces heparanase expression in estrogen receptor-positive breast cancer.
Cohen I; Maly B; Simon I; Meirovitz A; Pikarsky E; Zcharia E; Peretz T; Vlodavsky I; Elkin M
Clin Cancer Res; 2007 Jul; 13(14):4069-77. PubMed ID: 17634531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]